Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2025

Type / Class
Equity / Ordinary Shares, no par value
Symbol
WVE on Nasdaq
Shares outstanding
182,917,028
Price per share
$13.01
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
182,725,550
Total reported value
$3,107,724,831
% of total 13F portfolios
0%
Share change
+19,883,825
Value change
+$421,310,913
Number of holders
214
Price from insider filings
$13.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 13% -8% $169,771,577 25,453,010 0% RA Capital Management, L.P. 11 Dec 2025
FMR LLC 8.5% $255,356,705 15,020,983 FMR LLC 31 Dec 2025
Adage Capital Management, L.P. 5.4% -43% $139,157,787 -$74,376,843 9,786,061 -35% Adage Capital Management, L.P. 31 Dec 2025
BlackRock, Inc. 6.1% $63,555,507 9,360,163 BlackRock, Inc. 31 Dec 2024
MAVERICK CAPITAL LTD 5.4% $56,093,833 8,261,242 Maverick Capital, Ltd. 31 Dec 2024

As of 31 Dec 2025, 214 institutional investors reported holding 182,725,550 shares of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE). This represents 100% of the company’s total 182,917,028 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) together control 83% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GSK plc 10% 18,245,691 0% 39% $310,176,747
RA CAPITAL MANAGEMENT, L.P. 10% 18,203,009 +0.01% 3.2% $309,451,153
FMR LLC 8.3% 15,135,983 +195% 0.01% $257,311,705
BlackRock, Inc. 6.9% 12,648,907 +21% 0% $215,031,419
ADAGE CAPITAL PARTNERS GP, L.L.C. 5.4% 9,786,061 -33% 0.25% $166,363,037
MAVERICK CAPITAL LTD 5.1% 9,280,237 +11% 1.7% $157,764,029
PRICE T ROWE ASSOCIATES INC /MD/ 4% 7,407,372 +83% 0.01% $125,927,000
Darwin Global Management, Ltd. 4% 7,298,421 2.5% $125,167,920
Driehaus Capital Management LLC 3.6% 6,581,067 +4.5% 0.76% $111,878,139
M28 Capital Management LP 3.1% 5,664,548 0% 70% $96,297,316
FEDERATED HERMES, INC. 2.6% 4,744,520 +26% 0.13% $80,656,840
PRIMECAP MANAGEMENT CO/CA/ 2.2% 4,095,282 +116% 0.05% $69,619,794
683 Capital Management, LLC 2.2% 4,015,000 -3.3% 5.7% $68,255,000
VANGUARD GROUP INC 2% 3,573,746 +14% 0% $60,753,682
GEODE CAPITAL MANAGEMENT, LLC 1.7% 3,170,110 +8.6% 0% $53,902,133
STATE STREET CORP 1.6% 2,996,084 +5.3% 0% $50,933,428
GOLDMAN SACHS GROUP INC 1.6% 2,854,082 +34% 0.01% $48,519,394
Affinity Asset Advisors, LLC 1.5% 2,700,000 +29% 3.3% $45,900,000
EMERALD ADVISERS, LLC 1.3% 2,455,089 -18% 1.3% $41,736,513
Siren, L.L.C. 1.3% 2,450,000 -34% 1.2% $41,650,000
Kynam Capital Management, LP 1.2% 2,169,105 -52% 2.4% $36,874,785
LOOMIS SAYLES & CO L P 1.1% 2,040,223 -30% 0.04% $34,683,791
Pfizer Inc 1% 1,875,000 0% 13% $31,875,000
First Light Asset Management, LLC 1% 1,853,851 2.4% $31,515,467
Bellevue Group AG 0.81% 1,490,518 -64% 0.48% $25,338,806

Institutional Holders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 182,725,550 $3,107,724,831 +$421,310,913 $17.00 214
2025 Q3 143,680,189 $1,051,640,675 +$37,185,132 $7.32 187
2025 Q2 138,939,054 $903,136,388 +$46,387,682 $6.50 174
2025 Q1 131,293,097 $1,061,209,645 +$20,316,471 $8.08 192
2024 Q4 128,616,529 $1,591,015,441 +$86,595,360 $12.37 181
2024 Q3 120,246,621 $986,101,781 +$176,011,863 $8.20 160
2024 Q2 95,071,148 $474,405,111 +$9,854,270 $4.99 143
2024 Q1 92,759,614 $572,308,103 +$4,033,614 $6.17 131
2023 Q4 92,528,153 $468,029,084 +$93,144,169 $5.05 115
2023 Q3 72,598,087 $417,436,128 +$3,006,886 $5.75 85
2023 Q2 72,147,137 $262,614,478 +$6,429,830 $3.64 80
2023 Q1 70,086,593 $303,466,627 +$3,780,454 $4.33 72
2022 Q4 68,108,089 $476,736,473 +$7,420,705 $7.00 74
2022 Q3 67,256,615 $242,816,542 -$1,613,831 $3.61 58
2022 Q2 67,784,074 $220,297,785 +$69,127,143 $3.25 56
2022 Q1 47,551,964 $95,097,268 -$1,035,989 $2.00 77
2021 Q4 47,284,486 $148,479,513 +$13,347,500 $3.14 87
2021 Q3 37,428,616 $183,549,240 +$443,975 $4.90 84
2021 Q2 37,041,603 $246,689,021 -$5,849,970 $6.66 82
2021 Q1 38,281,847 $214,782,368 +$1,495,724 $5.61 97
2020 Q4 36,092,793 $284,070,815 -$9,567,182 $7.87 102
2020 Q3 37,117,728 $315,928,313 +$59,335,508 $8.49 106
2020 Q2 29,422,263 $306,287,769 -$6,711,423 $10.41 89
2020 Q1 30,100,828 $282,072,986 +$9,439,494 $9.37 76
2019 Q4 29,498,551 $236,424,963 -$44,351,424 $8.01 87
2019 Q3 30,879,604 $633,634,840 +$1,025,937 $20.53 86
2019 Q2 30,470,000 $794,421,079 +$39,569,951 $26.09 100
2019 Q1 29,400,279 $1,142,135,791 +$191,634,667 $38.85 109
2018 Q4 24,393,021 $1,025,484,934 +$23,061,213 $42.04 91
2018 Q3 23,803,148 $1,190,156,500 -$29,678,796 $50.00 92
2018 Q2 24,465,339 $935,797,108 +$30,300,014 $38.25 77
2018 Q1 23,663,816 $948,860,012 +$61,087,976 $40.10 79
2017 Q4 22,225,342 $780,113,100 +$59,933,498 $35.10 72
2017 Q3 20,492,602 $445,796,252 +$26,521,810 $21.75 58
2017 Q2 19,316,233 $359,305,882 +$66,970,759 $18.60 55
2017 Q1 15,709,867 $431,755,770 +$32,771,317 $27.50 49
2016 Q4 14,822,157 $388,292,611 +$18,199,344 $26.15 51
2016 Q3 14,061,056 $456,556,375 -$3,399,325 $32.47 45
2016 Q2 14,199,612 $293,778,139 +$6,802,315 $20.69 37
2016 Q1 14,000,592 $192,282,000 +$2,926,211 $13.88 22
2015 Q4 13,788,837 $218,726,000 +$196,226,000 $15.95 18